|
|
Article: Threshold Starts Glufosfamide Phase III In Pancreatic Cancer.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Threshold Pharmaceuticals Inc. began patient enrollment in a Phase III trial of glufosfamide for pancreatic cancer.
The pivotal study is designed to test the company's lead product in patients with metastatic pancreatic cancer refractory to first-line treatment. Its primary endpoint will compare the median survival of patients treated with glufosfamide and best supportive care to those solely receiving best supportive care - all medical or surgical interventions that a pancreatic cancer patient should receive to palliate the cancer but excluding treatment with systemic therapies intended to kill the cancer cells.
At present, ...
Related newspaper, magazine, and journal articles:
|
|
Article: MEGABIOS, GENEMEDICINE AGREE TO `STRATEGIC MERGER' THAT POOLS ...
BIOWORLD Today;
October 27, 1998 ;
700+ words
... ... percent, or $0.281. McGraw told BioWorld Today the move is one of the few "strategic ... into GeneMedicine," Weintraub told BioWorld Today. "This merger allows us to simplify ... up relatively early," Waldron told BioWorld Today. "This merger announcement is the ...
|
|